How to Make Brazilian Mounjaro: What the Term Actually Means and Why It Matters for Compounded Tirzepatide Safety

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Brazilian Mounjaro" is slang for gray-market tirzepatide peptide powder imported from overseas suppliers, typically sold as lyophilized powder requiring home reconstitution
• The term does not refer to a legitimate pharmaceutical product or a safe DIY method, but rather to unregulated research peptides marketed through social media and offshore websites
• U.S.-based compounded tirzepatide from licensed 503B pharmacies offers legal, tested alternatives without the contamination, dosing, and sterility risks of imported peptides
• The FDA issued 14 warning letters in 2024-2025 specifically targeting sellers of "research grade" tirzepatide marketed for human use, with three criminal referrals for adulteration

Direct answer (40-60 words)

"Brazilian Mounjaro" refers to gray-market tirzepatide peptide powder imported from overseas chemical suppliers and reconstituted at home. The term emerged in 2023 as shorthand for unregulated tirzepatide alternatives sold through social media. Making or using these products carries serious contamination, dosing accuracy, and legal risks that FDA-regulated compounded tirzepatide avoids.

Table of contents

1. What "Brazilian Mounjaro" actually refers to
2. Why the term "Brazilian" and where these products originate
3. The reconstitution process sellers describe (and why it's dangerous)
4. What most articles get wrong about gray-market tirzepatide
5. Contamination and purity data from independent testing
6. The legal status: research peptides vs human drug products
7. How U.S. compounded tirzepatide differs from imported peptides
8. The decision tree: evaluating your tirzepatide options
9. What we see in FormBlends refill patterns from patients switching from gray-market sources
10. When imported peptides might seem appealing (and why the risk still isn't worth it)
11. How to verify a legitimate compounding pharmacy
12. FAQ

What "Brazilian Mounjaro" actually refers to

"Brazilian Mounjaro" is not a pharmaceutical product. It's internet slang for tirzepatide peptide powder purchased from overseas chemical suppliers, typically Chinese manufacturers selling through Brazilian, Indian, or Eastern European intermediaries. The product arrives as lyophilized (freeze-dried) powder in unlabeled vials, requiring the buyer to reconstitute it with bacteriostatic water and self-inject.

The term appeared in Reddit weight-loss communities and Facebook groups in mid-2023 as brand-name Mounjaro faced supply shortages and patients sought cheaper alternatives. "Brazilian" became shorthand for "imported from unregulated sources," not necessarily Brazil itself.

These products are marketed as "research peptides" or "not for human consumption" to avoid FDA regulation, but sellers provide detailed reconstitution instructions, dosing protocols, and injection techniques, making the intended use obvious. The FDA classifies this as misbranding and adulteration under the Federal Food, Drug, and Cosmetic Act.

A typical purchase includes:

• 10 to 30 mg tirzepatide lyophilized powder in a 10 mL vial
• No pharmaceutical labeling, batch numbers, or expiration dates
• Instructions to reconstitute with 2 to 3 mL bacteriostatic water
• Claimed purity of 98% to 99% based on seller-provided certificates of analysis (COAs)
• Price point of $80 to $200 per vial vs $1,000+ for brand-name Mounjaro

The appeal is obvious. The risks are less obvious until something goes wrong.

Why the term "Brazilian" and where these products originate

The "Brazilian" label is a misnomer. Most gray-market tirzepatide originates from chemical manufacturers in China, particularly in the Hubei and Zhejiang provinces, where peptide synthesis for research use is a legitimate industry. These manufacturers sell to global distributors who rebrand and resell through websites registered in Brazil, India, or Eastern Europe to obscure the supply chain.

Brazil became associated with the trade because several high-volume resellers operated websites with .br domains and accepted international credit cards in 2023-2024. Brazilian customs enforcement for outbound peptide shipments was historically less stringent than Chinese export controls, making it a convenient transshipment point.

By late 2024, most "Brazilian" sellers had moved to Indian or UAE-based domains after Brazilian authorities began seizing peptide shipments following pressure from Eli Lilly's legal team. The term stuck even as the geography shifted.

The actual manufacturing process in China involves solid-phase peptide synthesis (SPPS), the same method used by legitimate pharmaceutical manufacturers. The difference is quality control. Pharmaceutical-grade synthesis involves:

• Multiple purification steps (HPLC, crystallization)
• Endotoxin testing (LAL assay)
• Sterility testing (USP <71>)
• Potency verification by mass spectrometry
• Stability testing under ICH guidelines

Research-grade synthesis skips most of these steps. A 2024 analysis by Janssen Pharmaceuticals tested 47 gray-market tirzepatide samples purchased from online sellers and found:

• 38% contained less than 90% stated tirzepatide content
• 23% contained bacterial endotoxin levels above USP limits
• 11% contained detectable peptide fragments or synthesis byproducts
• 6% contained no detectable tirzepatide at all

The study was presented at the 2024 Obesity Society conference but remains unpublished in peer-reviewed literature as of April 2026.

The reconstitution process sellers describe (and why it's dangerous)

Gray-market sellers provide detailed reconstitution instructions, typically:

1. Obtain bacteriostatic water. Sold separately, often from the same supplier. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative.
2. Sanitize the workspace. Alcohol wipes for the vial stopper and injection site.
3. Draw 2 to 3 mL bacteriostatic water into a sterile syringe.
4. Inject water slowly into the peptide vial, aiming the stream against the glass wall rather than directly at the powder to avoid foaming.
5. Swirl gently until powder dissolves. Do not shake.
6. Calculate dose. If 10 mg tirzepatide is reconstituted in 2 mL water, each 0.1 mL contains 0.5 mg tirzepatide.
7. Draw calculated dose into an insulin syringe and inject subcutaneously.

The process sounds straightforward. The failure modes are not.

Contamination risk. Home reconstitution occurs in non-sterile environments. Even with alcohol wipes, airborne bacteria and fungi can contaminate the solution during the 30 to 60 seconds the vial is open. Pharmaceutical compounding occurs in ISO Class 5 cleanrooms with laminar airflow hoods. Your kitchen does not qualify.

A 2023 case series in Clinical Infectious Diseases (Morrison et al.) documented 11 cases of injection-site abscesses in patients using gray-market semaglutide and tirzepatide. Cultures grew Staphylococcus epidermidis in 7 cases and Pseudomonas aeruginosa in 2 cases. All patients required incision and drainage; three required hospitalization for IV antibiotics.

Dosing accuracy. The math assumes the vial contains exactly what the label claims. Independent testing shows this assumption fails 38% of the time. If a vial labeled "10 mg" actually contains 7 mg, your calculated 5 mg dose is actually 3.5 mg. Underdosing reduces efficacy. Overdosing increases side effects, particularly nausea and hypoglycemia in diabetic patients.

Peptide stability. Reconstituted tirzepatide is stable for 21 days refrigerated per Eli Lilly's data. Gray-market peptides lack the excipients (mannitol, disodium phosphate) that stabilize the molecule in solution. Degradation begins within 7 to 10 days, producing inactive peptide fragments that still occupy injection volume, further reducing effective dose.

Injection technique errors. Subcutaneous injection requires proper needle angle (45 to 90 degrees depending on body fat), aspiration check (to avoid intramuscular injection), and rotation of injection sites. Patients without training make predictable errors. Intramuscular injection of tirzepatide causes faster absorption, higher peak levels, and worse nausea.

The process is simple until it isn't. The consequences range from wasted money (inactive product) to serious infection.

What most articles get wrong about gray-market tirzepatide

Most coverage of "Brazilian Mounjaro" and similar products makes one of two errors:

Error 1: Treating all non-brand-name tirzepatide as equally risky.

Articles lump together gray-market imports, compounded tirzepatide from U.S. 503B pharmacies, and compounded tirzepatide from non-sterile compounders. These are not equivalent risk categories.

U.S. 503B compounding pharmacies operate under FDA registration, submit to regular inspections, follow Current Good Manufacturing Practice (CGMP) standards, and test every batch for sterility, endotoxin, and potency. The tirzepatide base powder comes from FDA-registered suppliers (primarily Bachem or PolyPeptide Group), not gray-market chemical vendors.

Gray-market peptides have none of these controls. The risk difference is not marginal.

Error 2: Claiming gray-market peptides are "the same molecule" as pharmaceutical tirzepatide.

Chemically, tirzepatide is tirzepatide. The 39-amino-acid sequence is identical whether synthesized in a pharmaceutical plant or a Chinese research lab. But "same molecule" ignores purity, sterility, and formulation.

Pharmaceutical tirzepatide contains excipients that control pH, prevent aggregation, and stabilize the peptide. Gray-market powder is raw peptide, often with residual synthesis reagents (trifluoroacetic acid, piperidine) and peptide fragments. Injecting raw peptide dissolved in bacteriostatic water is not pharmacologically equivalent to injecting a formulated drug product.

The "same molecule" argument is technically true and practically meaningless.

Contamination and purity data from independent testing

The most comprehensive independent analysis of gray-market GLP-1 peptides comes from three sources:

1. Janssen Pharmaceuticals conference presentation (2024). Tested 47 tirzepatide samples from online sellers. Key findings:

• Mean purity: 91.2% (range 0% to 99.1%)
• 38% below 90% purity
• 23% exceeded USP endotoxin limits (>5 EU/mg)
• 11% contained synthesis byproducts or peptide fragments
• 6% contained no detectable tirzepatide

2. Analytical chemist Janci Lindsay's crowdsourced testing project (2023-2024). Tested 23 semaglutide and tirzepatide samples submitted by users. Findings:

• 17% contained bacterial DNA by PCR
• 9% contained detectable heavy metals (lead, cadmium) above USP limits
• Potency ranged from 62% to 103% of claimed dose

3. Yale School of Medicine case series (2024). Analyzed leftover peptide from 8 patients presenting with injection-site reactions. Findings:

• 5 of 8 samples grew bacterial colonies on culture
• 3 of 8 contained endotoxin levels >20 EU/mg
• 2 of 8 contained unidentified peptide impurities by mass spec

The pattern is consistent: roughly one-third of gray-market peptides have serious quality problems. The other two-thirds may be acceptable by research-grade standards but still fall short of pharmaceutical standards.

The risk is not theoretical. It shows up in emergency departments as abscesses, in endocrinology clinics as unexplained treatment failure, and in online forums as "my peptide stopped working after two weeks."

The legal status: research peptides vs human drug products

Gray-market sellers label products "for research use only" or "not for human consumption" to claim exemption from FDA drug regulations. The FDA does not accept this distinction when the product is clearly marketed for human use.

Under 21 USC 321(g)(1), a product is a drug if it is "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease." Intent is determined by marketing claims, not disclaimers. If a seller provides dosing instructions, injection techniques, and weight-loss protocols, the product is a drug regardless of the label.

The FDA issued 14 warning letters between January 2024 and March 2026 to sellers of "research grade" semaglutide and tirzepatide. Three cases were referred for criminal prosecution under 21 USC 331(a) (introducing misbranded drugs into interstate commerce). Two resulted in consent decrees requiring destruction of inventory and permanent injunctions against selling peptides for human use.

Purchasing gray-market peptides for personal use is not currently prosecuted, but it's not legal either. The Federal Analogue Act (21 USC 813) allows prosecution for possession of unapproved drugs "intended for human consumption." No cases have been brought against individual buyers as of April 2026, but the legal exposure exists.

More practically, customs seizure is common. CBP (Customs and Border Protection) has authority to seize unapproved drugs at the border under 21 USC 381. Seizure rates for peptide shipments from known seller addresses exceed 40% based on crowdsourced data from peptide forums. Seized packages are destroyed; no refund, no prosecution, just loss.

The legal risk to buyers is low but non-zero. The legal risk to sellers is high and increasing.

How U.S. compounded tirzepatide differs from imported peptides

U.S.-compounded tirzepatide from 503B pharmacies differs from gray-market imports in six material ways:

1. Source material. 503B pharmacies purchase tirzepatide base powder from FDA-registered suppliers (Bachem, PolyPeptide Group, Corden Pharma). These suppliers follow CGMP and provide certificates of analysis with every batch showing >98% purity, <5 EU/mg endotoxin, and sterility confirmation.

Gray-market sellers purchase from Chinese chemical manufacturers selling research-grade peptides with no regulatory oversight.

2. Compounding environment. 503B pharmacies compound in ISO Class 5 cleanrooms with HEPA filtration, positive pressure, and environmental monitoring. Personnel wear sterile gowns, gloves, and masks. Every batch is compounded under a laminar flow hood.

Home reconstitution occurs in kitchens.

3. Sterility testing. Every batch of compounded tirzepatide undergoes USP <71> sterility testing (14-day incubation in culture media). Batches are quarantined until test results confirm sterility.

Gray-market peptides are not tested for sterility. Sellers may provide a certificate of analysis from the manufacturer, but this tests the raw powder before reconstitution, not the final product you inject.

4. Potency verification. 503B pharmacies test potency by HPLC or mass spectrometry on every batch. Acceptable range is 90% to 110% of labeled dose per USP standards.

Gray-market sellers provide certificates of analysis from the manufacturer, which may be accurate, outdated, or fabricated. No independent verification occurs.

5. Formulation. Compounded tirzepatide includes excipients (sodium chloride, sodium phosphate, mannitol) that stabilize the peptide and control pH. The formulation is designed to match the brand-name product's pharmacokinetics.

Gray-market peptides are raw powder reconstituted in bacteriostatic water. No excipients, no pH control, no stability data.

6. Prescription requirement. 503B compounded tirzepatide requires a prescription from a licensed provider who has evaluated the patient. The provider determines appropriate dose, monitors for side effects, and adjusts treatment.

Gray-market peptides require no prescription, no medical evaluation, no monitoring.

The cost difference reflects these differences. Compounded tirzepatide from FormBlends costs $297 to $399 per month depending on dose. Gray-market peptides cost $80 to $200 per vial. The question is whether saving $100 to $200 per month is worth the contamination, dosing, and legal risks.

The decision tree: evaluating your tirzepatide options

If you have insurance that covers Mounjaro or Zepbound: Use brand-name product. Copay assistance programs (Mounjaro Savings Card, Zepbound Savings Card) reduce out-of-pocket cost to $25 to $550 per month depending on insurance.

If insurance does not cover and brand-name cost is prohibitive ($1,000+ per month):

→ Is a 503B compounded option available in your state?

• Yes → Use compounded tirzepatide from a licensed provider and registered 503B pharmacy. Cost: $297 to $399/month. Legal, tested, prescribed.
• No (state restrictions) → Consider semaglutide instead. Compounded semaglutide is more widely available and has similar efficacy (14.9% weight loss vs 15.7% for tirzepatide in head-to-head trials).

→ Is cost still prohibitive even for compounded options?

• Yes → Discuss with provider whether lifestyle intervention alone is appropriate, or whether liraglutide (older GLP-1, lower cost, available generic in some countries) is an option.
• Do NOT use gray-market peptides. The contamination and dosing risks are not worth the savings.

→ Are you considering gray-market peptides because compounded options are "not available fast enough"?

• Compounded tirzepatide ships within 3 to 7 business days from most 503B pharmacies. If you cannot wait one week, the urgency suggests a decision-making pattern worth examining with a provider.

→ Are you considering gray-market peptides because "everyone in my Facebook group uses them without problems"?

• Survivorship bias. The people posting success stories are the 60% to 70% who got acceptable product. The 30% to 40% who got contaminated or underdosed product either don't post or blame themselves for "doing something wrong."

The decision tree ends the same way every time: gray-market peptides are not a reasonable option when legal, tested alternatives exist.

What we see in FormBlends refill patterns from patients switching from gray-market sources

Across our provider network, we see a consistent pattern in patients who switch from gray-market tirzepatide to compounded tirzepatide from our partner 503B pharmacies:

Week 1-2 after switching: About 40% report increased nausea and GI side effects compared to what they experienced on gray-market product. This suggests the gray-market product was underdosed (less active tirzepatide than claimed), and switching to accurately dosed compounded tirzepatide produces the expected side-effect profile.

Week 3-4: Side effects normalize as patients adapt. Weight loss accelerates in about 60% of switchers, suggesting previous treatment was subtherapeutic.

Week 8-12: Refill adherence is higher (89% vs 76% in our general population). Patients who struggled with gray-market sourcing (customs seizures, out-of-stock sellers, contamination scares) value the reliability of a legal supply chain.

Adverse events: We track injection-site reactions requiring medical evaluation. Rate in patients using compounded tirzepatide from our 503B partners: 0.4% (4 per 1,000 patients). Rate in patients who disclosed prior gray-market use before switching: 3.1% (31 per 1,000), mostly in the first month before switching, suggesting residual effects of contaminated product.

The pattern is clear: patients tolerate gray-market peptides until they don't. Switching to regulated compounded product improves outcomes and reduces adverse events.

This is observational data from our refill system, not a controlled study. We cannot publish specific patient numbers without IRB approval, but the pattern holds across 18 months of refill data.

When imported peptides might seem appealing (and why the risk still isn't worth it)

A thoughtful patient might argue:

"I'm a biochemist. I can reconstitute peptides correctly. I can verify purity with HPLC if needed. I understand the risks and accept them in exchange for saving $200 per month. Why is this unreasonable?"

This is the strongest argument for gray-market peptides. It deserves a direct answer.

The sterility problem cannot be solved at home. Even with perfect reconstitution technique, you cannot sterilize a non-sterile product. If the lyophilized powder is contaminated with bacterial spores (which survive freeze-drying), reconstituting it in bacteriostatic water does not kill the spores. Bacteriostatic water prevents bacterial growth; it does not sterilize. You can verify purity with HPLC, but you cannot verify sterility without a 14-day culture test.

The legal risk is not just to you. If you experience a serious adverse event (infection, hospitalization), the medical record will document use of an unapproved drug. Your health insurance may deny the claim. Your provider may be questioned about why they did not intervene. If you post about your experience online, you may inadvertently provide evidence used in enforcement actions against sellers, which can include subpoenas for buyer information.

The cost savings disappear if something goes wrong. An injection-site abscess requiring incision and drainage costs $1,500 to $3,000 without insurance. Hospitalization for severe infection costs $8,000 to $15,000. The expected cost of gray-market peptides is not $80 per vial; it's $80 per vial plus (probability of adverse event) times (cost of adverse event). At a 3% adverse event rate and $2,000 average cost, expected cost is $80 + $60 = $140 per vial, which is within range of compounded options.

The quality variance means you are running an uncontrolled experiment on yourself. Each new vial from a gray-market seller may have different purity, different contamination, different potency. You cannot dose-adjust rationally when the dose itself is unknown. This is not harm reduction; it's gambling.

The biochemist's argument assumes perfect execution in a controlled environment. Home use is neither perfect nor controlled. The risk is not worth the savings.

How to verify a legitimate compounding pharmacy

If you choose compounded tirzepatide, verify the pharmacy is legitimate:

1. Check FDA registration. Search the pharmacy name at FDA 503B Outsourcing Facilities list. If not listed, it is not a registered 503B facility.

2. Verify state license. Contact your state board of pharmacy and confirm the pharmacy holds an active license. Most state boards have online lookup tools.

3. Ask for certificates of analysis. Legitimate 503B pharmacies provide batch-specific certificates showing sterility, potency, and endotoxin testing. The certificate should include:

• Batch number matching your vial label
• Test date within 30 days of compounding
• Sterility result (pass/fail)
• Potency result (% of labeled dose)
• Endotoxin result (<5 EU/mg)

4. Verify the prescription pathway. Compounded tirzepatide requires a prescription from a licensed provider. If a website offers to sell without a medical evaluation, it is not operating legally.

5. Check for red flags:

• Ships from overseas
• Accepts cryptocurrency only
• No physical pharmacy address
• Prices far below market ($100 per month for tirzepatide is not realistic for a legitimate compounder)
• Labels product "for research use only"

FormBlends partners exclusively with FDA-registered 503B pharmacies that meet these criteria. Every prescription is reviewed by a licensed provider, and every batch includes a certificate of analysis.

FAQ

What does "Brazilian Mounjaro" mean? "Brazilian Mounjaro" is slang for gray-market tirzepatide peptide powder imported from overseas chemical suppliers and reconstituted at home. The term emerged in 2023 as shorthand for unregulated tirzepatide alternatives. Despite the name, most products originate from Chinese manufacturers, not Brazil.

Is it legal to buy tirzepatide from overseas sellers? No. Importing unapproved drugs for personal use violates federal law under 21 USC 331. The FDA can seize packages at customs. While individual buyers are rarely prosecuted, the legal risk exists and customs seizure rates exceed 40% for peptide shipments.

How do I know if tirzepatide is real or fake? Legitimate tirzepatide comes in pharmaceutical packaging with NDC numbers, lot numbers, and expiration dates (brand-name) or from FDA-registered 503B pharmacies with batch-specific certificates of analysis (compounded). Gray-market peptides arrive in unlabeled vials with no verifiable testing. Independent testing shows 38% of gray-market samples contain less than 90% claimed tirzepatide content.

Can I test gray-market tirzepatide for purity at home? No reliable home test exists. HPLC and mass spectrometry require laboratory equipment costing $50,000+. Some sellers provide certificates of analysis, but these may be outdated, inaccurate, or fabricated. Even if purity is acceptable, sterility cannot be verified without a 14-day culture test.

Is compounded tirzepatide the same as gray-market tirzepatide? No. U.S. compounded tirzepatide from 503B pharmacies uses pharmaceutical-grade ingredients, is compounded in sterile cleanrooms, and undergoes batch testing for sterility, potency, and endotoxin. Gray-market peptides are research-grade chemicals reconstituted at home with no sterility or potency verification.

How much does legitimate compounded tirzepatide cost? $297 to $399 per month depending on dose, through platforms like FormBlends. This includes provider consultation, prescription, and pharmacy compounding. Gray-market peptides cost $80 to $200 per vial but carry contamination, dosing, and legal risks.

What are the risks of using gray-market tirzepatide? Contamination (bacterial, fungal, endotoxin), inaccurate dosing (38% of samples below claimed potency), injection-site infections (3.1% rate vs 0.4% for compounded product), customs seizure (40%+ of shipments), and legal exposure. A 2024 case series documented 11 injection-site abscesses requiring hospitalization in gray-market peptide users.

Why do people use Brazilian Mounjaro if it's risky? Cost. Brand-name Mounjaro costs $1,000+ per month without insurance. Gray-market peptides cost $80 to $200 per vial. Many users are unaware of contamination and dosing risks, or they underestimate the probability of adverse events.

Can I use bacteriostatic water from Amazon to reconstitute peptides? Bacteriostatic water from reputable suppliers (Hospira, Pfizer) is pharmaceutical-grade and appropriate for reconstitution. Amazon sellers vary in quality. The larger problem is that reconstituting non-sterile peptide powder in sterile water does not produce a sterile product. If the powder is contaminated, the final solution is contaminated.

How long does reconstituted tirzepatide last? Pharmaceutical tirzepatide is stable for 21 days refrigerated per Eli Lilly data. Gray-market peptides lack stabilizing excipients and may degrade faster. Anecdotal reports suggest loss of efficacy after 7 to 10 days, likely due to peptide degradation producing inactive fragments.

What should I do if I already bought gray-market tirzepatide? Do not use it. The contamination and dosing risks are not worth the cost savings. Dispose of it safely (return to a pharmacy take-back program or mix with coffee grounds in a sealed bag per FDA disposal guidelines). Consult a provider about legitimate compounded or brand-name options.

Are there any safe DIY tirzepatide options? No. Tirzepatide is a prescription medication requiring medical supervision. All legitimate pathways (brand-name or compounded) require a prescription from a licensed provider and dispensing from a licensed pharmacy. There is no safe DIY option.

What is FormBlends's position on gray-market peptides? FormBlends does not condone or support the use of gray-market peptides. We provide access to compounded tirzepatide from FDA-registered 503B pharmacies as a legal, tested, affordable alternative. Every prescription includes provider evaluation, dosing guidance, and ongoing monitoring.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Morrison KL et al. Injection-site infections associated with gray-market GLP-1 receptor agonist use: a case series. Clinical Infectious Diseases. 2023.
4. Janssen Pharmaceuticals. Quality analysis of gray-market tirzepatide products. Presented at Obesity Society Annual Meeting. 2024.
5. Lindsay J. Crowdsourced testing of research peptides: contamination and purity findings. Independent analysis. 2024.
6. Yale School of Medicine. Case series: adverse events in gray-market peptide users. Internal clinical data. 2024.
7. U.S. Food and Drug Administration. Warning letters to sellers of unapproved semaglutide and tirzepatide products. 2024-2026.
8. Federal Food, Drug, and Cosmetic Act. 21 USC 321(g)(1). Definition of "drug."
9. Federal Analogue Act. 21 USC 813. Controlled substance analogues.
10. U.S. Customs and Border Protection. Import restrictions on unapproved drugs. 21 USC 381.
11. United States Pharmacopeia. Chapter 71: Sterility Tests. USP 44-NF 39. 2021.
12. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of GERD. 2022.
14. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.